Drug: ZOLADEX Injury: Malignant neoplasm progression Quarter: 2016Q3
Total Records: 7 Number of Pages: 1
Event ID | DRUGNAME | PT | Drug Manufacturer | Patient Age | Sex | Weight | Date (YYYYMMDD) | Country |
---|---|---|---|---|---|---|---|---|
124665312 | ZOLADEX | Malignant neoplasm progression | ASTRAZENECA | 30944.00 DY | M | 0 | 20160909 | NL |
125278771 | ZOLADEX | Malignant neoplasm progression | ASTRAZENECA | 39.00 YR | F | 0 | 20160705 | GB |
126411261 | ZOLADEX | Malignant neoplasm progression | ASTRAZENECA | 0.00 | F | 0 | 20160810 | CN |
126485643 | ZOLADEX | Malignant neoplasm progression | ASTRAZENECA | 67.00 YR | M | 0 | 20160930 | CN |
127159062 | ZOLADEX | Malignant neoplasm progression | ASTRAZENECA | 29662.00 DY | M | 0 | 20160921 | NL |
127564261 | ZOLADEX | Malignant neoplasm progression | ASTRAZENECA | 45.00 YR | F | 0 | 20160916 | BE |
127766201 | ZOLADEX | Malignant neoplasm progression | ASTRAZENECA | 70.00 YR | M | 0 | 20160923 | RU |
Total Records: 7 Number of Pages: 1